# Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

> **NCT00706862** · PHASE3 · UNKNOWN · sponsor: **Agennix** · enrollment: 1100 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Talactoferrin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00706862
- **Lead sponsor:** Agennix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-02
- **Primary completion:** 2015-06
- **Final completion:** 2016-03
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2012-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00706862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00706862, "Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00706862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*